Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Best corrected visual acuity
研究概览
简要总结
Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER therapy, antivascular endothelial growth factor (VEGF), and triamcinolone.
Aim To detect the efficacy of formulated Triamcinolone Acetonide(TA) injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diminution of vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch
- •CMT ≥ 250 µ,
- •Willing to participate in the study.
排除标准
- •Unwilling to participate in the study
- •Ischemic RVO
- •previous laser treatment
- •Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris
- •patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion
- •Cardiac co-morbidities result in significant hemodynamic changes
- •Respiratory diseases need treatment with antibiotics
- •Suffering from other chronic diseases as diabetes
- •Patient with allergy from triamcinolone acetonide.
研究组 & 干预措施
Formulated Posterior Sub Tenon Triamcinolone
All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.
干预措施: Triamcinolone Acetonide (Drug)
结局指标
主要结局
Best corrected visual acuity
时间窗: at 6th month
Measured by snellen chart
Central macular thickness
时间窗: at 6th month
Measured by Optical coherence tomography (OCT)
次要结局
未报告次要终点
研究者
Akram Fekry Elgazzar
Clinical Professor
Al-Azhar University